Why is this an inflection point? Appearing on CNBC’s Closing Bell Overtime during Recursion’s recent Download Day, Chris Gibson shared the Company’s major pipeline, platform and partnership updates. ◾ On the pipeline: 7 readouts in the next 18 months in our clinical programs – including 5 efficacy readouts. ◾ On partnerships: Bayer, one of our close partners, is going to be using one of our LLM software tools called LOWE as part of our partnership. “I think this really represents one of the first times a large pharmaceutical company is going to be adopting these AI tools in the way they discover and develop medicines together with us." ◾ On the platform: We are now operating the fastest supercomputer in all of pharma, built with NVIDIA. ◾ On the value proposition: “We’ve been able to demonstrate that using these tools, we can roughly 3x the speed of developing and discovering medicines toward the clinic and dramatically reduce the cost.” The most important measure? “Improving the probability of success.” The message to investors was clear: “Machine learning and AI are the right tools when you bring the right data and the right compute to bear to help us make sense and really decode biology.” Watch the full interview: https://lnkd.in/e_CthC37 #techbio #ai #pharma #biopharma #biotech #llm #downloadday
Recursion CEO Chris Gibson talks integrating AI into drug development process
https://www.youtube.com/
Congratulations, Chris Gibson and team.
Innovative Leadership in Talent Solutions: Founder & CEO of Recruits Lab & BioJobs Lab, Driving Organizational Success through Cutting-Edge Recruitment Strategies.
1moExciting updates from Recursion! It's incredible to see the strides in AI and pharma integration. The pipeline updates and partnerships, especially with Bayer, are paving the way for transformative advancements. Looking forward to seeing how these innovations accelerate medicine development and enhance success rates in pharmaceuticals. #Recursion #AI #Pharma #Biotech #LLM